Lupus anticoagulant detection kit

Abstract

The invention discloses a lupus anticoagulant detection kit. The lupus anticoagulant detection kit comprises an LA1 screening reagent and an LA2 confirmation reagent, the LA1 screening reagent comprises recombinant snake venom enzyme, recombinant phospholipid, calcium ions, a first heparin neutralizer, a first buffer solution and a first auxiliary material, and the LA1 screening reagent is in a liquid state; the LA2 confirmation reagent comprises recombinant snake venom enzyme, recombinant phospholipid, calcium ions, a second heparin neutralizer, a second buffer solution and a second auxiliary material, and the LA2 confirmation reagent is in a liquid state; the content of the recombinant phospholipid in the LA1 screening reagent is lower than that of the recombinant phospholipid in the LA2 confirmation reagent; the recombined snake venom enzyme and the recombined phospholipid are matched for use, the reagent sensitivity is higher, the change amplitude in unit time is remarkably enhanced when a positive or weak positive sample is tested, the detection rate of the positive sample is increased, and false negative is reduced; the kit also comprises a heparin neutralizer, so that the influence of heparin is eliminated, and the accuracy is improved; the reagent is liquid, convenient to use, low in cost and good in stability.

Description

technical field [0001] The invention relates to the field of biotechnology, in particular to a lupus anticoagulant detection kit. Background technique [0002] Lupus anticoagulant (LA) is a group of immunoglobulins that can directly bind to negatively charged phospholipids or to phospholipid protein complexes, belonging to antiphospholipid antibodies (APL). Persistent LA-positive patients are considered to have a higher risk of thrombosis and recurrence, and are also a danger signal for unexplained habitual abortion, stillbirth, thrombophilia, and certain autoimmune diseases; LA also enhances platelet aggregation and inhibits fibrinolytic activity Therefore, LA-positive patients are prone to thrombotic complications. [0003] At present, the commonly used methods for the detection of LA are activated partial thromboplastin time (APTT), modified dilute Russell viper venom time (dRVVT) and silica clotting time (SCT) assays. , the presence or absence of LA is usually judged b...

AI Technical Summary

Problems solved by technology

[0004] However, the mainstream lupus anticoagulant detection kits (dRVVT method) on the market are all in the form of freeze-dried powder. The freeze-drying process is too complicated, and the difference between reagent bottles is large. Reconstitution is required before use, which increases manual operations. steps, and is easily affected by reconstitution water quality, pipette accuracy, and operator techniques; the sensitivity of the lupus anticoagulant detection kit (dRVVT method) needs to be improved, especially for the presence of weak LA in the sample to be tested. False negative results often occur; the stability of the lupus anticoagulant detection kit (dRVVT method) needs to be improved, and the validity period is not long enough, which is not conducive to customer use and reagent storage, so it is very necessary to improve the stability of the reagent; The existing lupus anticoagulant detection kit (dRVVT method) has insufficient anti-heparin interference ability, and the results obtained are unreliable when encountering heparin-containing samples, so it is urgent to improve the anti-heparin interference ability of the existing kit; lupus anticoagulant Most of the detection kits (dRVVT method) are imported from abroad, the kits are expensive, the transportation time is long, and the arrival cycle is long, which has caused a certain degree of impact on hospitals and patients

Images